Results 11 to 20 of about 10,001 (276)
Critical Care Explorations, 2023 IMPORTANCE AND OBJECTIVES:. This study assessed the potential advantages of treating hepatorenal syndrome-acute kidney injury (HRS-AKI) with terlipressin versus placebo in the ICU setting. DESIGN:.
Constantine J. Karvellas, MD +3 more
doaj +2 more sources
Severe Bradycardia Associated with the Use of Terlipressin: A Case Report
Case Reports in GastroenterologyIntroduction: Although terlipressin is known to cause bradycardia, this adverse effect is usually described in association with hypertension and is considered a benign compensatory response mediated by arterial baroreceptors.
Alex Yartsev, Jessica T. Nguyen
doaj +2 more sources
PLoS ONEThe treatment of choice for hepatorenal syndrome-acute kidney injury (HRS-AKI) is vasoconstrictor therapy in combination with albumin, preferably norepinephrine or terlipressin as recommended by recent guidelines.
Jody C Olson, Ram M Subramanian
doaj +2 more sources
Gastroenterology Insights, 2023 Hepatorenal syndrome stands as one of several potential triggers of acute kidney injury in individuals grappling with either acute or persistent liver ailments. The nature of the decline in kidney function has led to the identification of two variants of
Ahlam Ayyad, Rami A. Al-Horani
doaj +2 more sources
Effectiveness and safety evaluation of terlipressin in the treatment of intestinal paralysis in end-stage liver disease [PDF]
BMC GastroenterologyBackground and aims Intestinal paralysis is a common complication in end-stage liver disease (ESLD), our aim is to assess the effectiveness and safety of low-dose terlipressin for treating intestinal paralysis in ESLD.
Xia Wan +7 more
doaj +2 more sources
Efficacy of low doses of terlipressin to prevent intra-operative blood loss in obstetrics
Вестник анестезиологии и реаниматологии, 2020 The use of modern blood-saving technologies is one of the effective methods of preventing intra-operative bleeding in obstetric practice, however, the effect of local use of terlipressin to reduce blood loss is not sufficiently investigated.The objective:
Yu. S. Аleksandrovich +4 more
doaj +3 more sources
Terlipressin for Hepatorenal Syndrome in Patients With Early-Stage Acute-on-Chronic Liver Failure. [PDF]
Liver IntABSTRACT Background & Aims Hepatorenal syndrome‐acute kidney injury (HRS‐AKI) is a life‐threatening complication of decompensated cirrhosis. The US Food and Drug Administration approved terlipressin use for HRS‐AKI based on the CONFIRM study, which demonstrated a significant improvement in HRS reversal with terlipressin versus placebo.
Rockey DC +7 more
europepmc +2 more sources
Bradycardia and Other Arrhythmias in Patients With Hepatorenal Syndrome-Acute Kidney Injury Following Terlipressin Treatment: A Pooled Analysis of Three North American Phase III Clinical Studies. [PDF]
Aliment Pharmacol TherIn a pooled analysis, bradycardia was observed in 6% of terlipressin‐treated patients but rarely required a dose interruption or reduction. Arrhythmia serious adverse event incidences were low and similar in both treatment groups. Routine intensive cardiac monitoring for the detection of arrhythmias may not be necessary during terlipressin ...
Bajaj JS +6 more
europepmc +2 more sources
Challenges in the Treatment of Hepatorenal Syndrome-Acute Kidney Injury: A US Chart Review of Treatment Patterns and Survival Outcomes. [PDF]
JGH OpenABSTRACT Background Treatments for hepatorenal syndrome with acute kidney injury (HRS‐AKI) that are not FDA‐approved have been widely used in the United States (US) with variable outcomes. This study describes the practice patterns, outcomes, and healthcare utilization around vasopressor use before terlipressin approval in 2022. Methods A retrospective
Sanyal AJ +12 more
europepmc +2 more sources